MCS
The Marcus Corporation
MCS has a slight edge over META overall, supported by stronger fundamentals and stronger modeled upside.
META
Meta Platforms, Inc.
META offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
MCS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
MCS's revenue, profitability, cash flow and balance sheet are all currently healthy.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MCS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 31x | $27.22 | — |
| Cheap | 32x | $24.94 | -8.4% |
| Current | 34x | $27.22 | — |
| Fair | 42x | $33.12 | +22% |
| Expensive | 429x | $339 | +1145% |
Historical ranges are pointers, not guarantees.
MCS's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 31x next year's earnings.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META has the edge over MCS in the historical PE scenario, which offers more potential upside but is not a forecast.
MCS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect MCS's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
MCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.87 | +10% |
| Q3 2026 | $0.79 | +216% |
| Q2 2026 | $0.71 | +54% |
| Q1 2026 | $0.44 | +$0.84 |
| Q4 2025 | $0.41 | +$0.65 |
| Q3 2025 | $0.25 | +$0.49 |
| Q2 2025 | $0.46 | +$1.13 |
| Q1 2025 | -$0.40 | -238% |
| Q4 2024 | -$0.24 | -167% |
MCS's earnings per share have fallen from their peak: $0.79 over the past year, against $1.35 in late 2019.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META earned $29.32 per share over the past year, up 30% from the year before.
MCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $237.8M | +13% |
| Q2 2026 | $231.7M | +12% |
| Q1 2026 | $154.4M | +3.8% |
| Q4 2025 | $193.5M | +2.8% |
| Q3 2025 | $210.2M | -9.7% |
| Q2 2025 | $206M | +17% |
| Q1 2025 | $148.8M | +7.4% |
| Q4 2024 | $188.3M | +17% |
MCS's revenue has grown year over year for four quarters in a row: $238M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +1.9 points |
| Q2 2026 | 12% | +5.4 points |
| Q1 2026 | -12% | +1.3 points |
| Q4 2025 | 0.9% | +2.1 points |
| Q3 2025 | 11% | -3.3 points |
| Q2 2025 | 6.3% | +5 points |
| Q1 2025 | -14% | -1.7 points |
| Q4 2024 | -1.2% | -1.9 points |
MCS's operating margin was 13% last quarter, up 1.9 points from the same quarter a year ago, near the top of its range since 2019.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over MCS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META has the edge over MCS on profitability, with a higher operating margin.
MCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.4M | +56% |
| Q2 2026 | $44M | +198% |
| Q1 2026 | -$21.9M | +$36.5M |
| Q4 2025 | $26.4M | -2.7% |
| Q3 2025 | $18.2M | +51% |
| Q2 2025 | $14.7M | -8.7% |
| Q1 2025 | -$58.3M | -$27.8M |
| Q4 2024 | $27.1M | +29% |
MCS has the edge over META on cash flow, with more consistent year-over-year improvement.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $28.6B over the past year.
MCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +455K shares |
| 1 year | +1.1% | +329K shares |
| 3 years | -23% | -9.5M shares |
| 5 years | +0.3% | +100K shares |
| Available history | +1.1% | +352K shares |
MCS has 32M diluted shares, up 1.1% from a year ago.
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has the edge over MCS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
MCS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 1.4x | Healthy |
MCS's net debt is less than a year of its operating earnings (EBITDA), down from 1.9 years a year ago.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META has the edge over MCS on leverage, with a lower net debt burden relative to earnings.
MCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.6 | Neutral |
| Stochastic | 21.4 | Neutral |
MCS's weekly RSI is 59 (neutral) and its Stochastic is 21 (neutral).
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
MCS PE vs Communication Services Sector
| Metric | MCS | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 16x | 109% above |
| PE % | 23 | 26 | 3 pts below |
MCS is trading at 34x earnings, a 109% premium to the Communication Services sector's median of 16x.
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META has the edge over MCS on valuation relative to its sector.
MCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 0.4% below |
| 20 week MA | $27.1 | 0.6% above |
| 50 week MA | $21.3 | 28% above |
| 100 week MA | $19.2 | 42% above |
| 200 week MA | $17.1 | 59% above |
MCS has the edge over META on trend strength, trading above more of its moving averages.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has fallen below most of its moving averages, though it's still 21% above its 200-week average.
MCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.9 | $12.5 | -61% |
| 2021 | $12.5 | $17.9 | +44% |
| 2022 | $17.9 | $13.9 | -22% |
| 2023 | $13.9 | $14.6 | +4.8% |
| 2024 | $14.6 | $21.4 | +47% |
| 2025 | $21.4 | $15.4 | -28% |
| 2026 YTD | $15.4 | $27.2 | +77% |
MCS has the edge over META on returns for 2026, with the stronger performance.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META's yearly returns have swung widely, from +200% in 2023 to −65% in 2022. It's down 6% so far in 2026.